Beam FDA alignment could accelerate review, says William Blair

William Blair views Beam Therapeutics (BEAM)’ update last night positively, saying it indicates the company has “clear line of sight” into the data packages necessary to support applications for risto-cel and BEAM-302. Acceptance of both programs into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot program could also aide in accelerating the clinical development and regulatory review process, the analyst tells investors in a research note. Blair expects the near-term BEAM-302 data update to be key a catalyst for the stock. It keeps an Outperform rating on Beam Therapeutics. The stock in morning trading is up 29% to $35.54.